TransMedics Group Inc
Chiusa
SettoreSettore sanitario
73.67 -2.19
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
72.59
Massimo
75.5
Entrata | -98M 7.3M |
|---|---|
Vendite | 13M 174M |
P/E Media del settore | 17.279 49.712 |
EPS | 0.3 |
Margine di Profitto | 4.206 |
Dipendenti | 898 |
EBITDA | -4.9M 28M |
Raccomandazioni | Acquista |
|---|---|
Previsioni per 12 mesi | +59.25% upside |
Utili prossimi | 29 lug 2026 |
|---|
Capitalizzazione di Mercato | -744M 2.6B |
|---|---|
Apertura precedente | 75.86 |
Chiusura precedente | 73.67 |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
128 / 342 Classifica in Healthcare
TransMedics Group Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.